IDXXIdexx Laboratories
Is the price fair?
The yardsticks disagree: cheap against its own 5-year P/E range (0th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.
Priced for ~13% a year FCF growth. The price demands more than its three-year revenue growth of 9% a year, priced for acceleration.
Cheap vs its own history: P/E 36.4 vs a 52.3 median over 41 quarters (−30% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What IDXX's price assumes
Idexx Laboratories trades at 36.4× earnings against 35.2× for the median Diagnostics & Research name, more expensive than its own group.
Trailing P/E · Diagnostics & Research median 35.2 · 1.04× the median: the market pays up for this one
- Price / sales
- 9.74
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 2.8%
Free cash flow yield · Diagnostics & Research median 3.7%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +28% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 27.5
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 30.8
- EV / salestoday's price, trailing year to Jun 30, 2026
- 9.87
- Healthcare median P/E509 names
- 26.2
- Diagnostics & Research median P/E33 names
- 35.2
- Free cash flow, trailing twelve months
- $1.25B
- Market capitalisation
- $44.3B
- 3-year revenue growth
- +9.0%
- 3-year free cash flow growth
- +28%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $681.12 |
| Its own P/E history, median | $744.50 |
| Its own P/E history, upper quartile | $856.44 |
| 52-week range | $504.59 – $766.68 |
| Today | $518.01 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry